Communiqués Inhibitor Therapeutics, Inc.

Actions

INTI

US45720M1053

Recherche biotechnologique et médicale

Temps Différé OTC Markets 21:01:31 23/09/2026			Varia. 5j.	Varia. 1 janv.
0,1000 ^USD	+69,49%		+12,49%	+122,22%

14/08	Inhibitor Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
15/05	Inhibitor Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

08/09	Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting	AQ
31/03	Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome	AQ
22/08/24	Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan	AQ
20/12/23	Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board	AQ
13/12/23	Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University	PR
31/05/23	INHIBITOR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
31/03/23	INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
19/12/22	INHIBITOR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Changes in Control or Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
15/09/22	Inhibitor Therapeutics : NOTICE OF PENDENCY OF DERIVATIVE AND CLASS ACTIONS, PROPOSED SETTLEMENT AND SETTLEMENT HEARING - Form 8-K	PU
15/09/22	INHIBITOR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/08/22	INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
03/06/22	INHIBITOR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
13/05/22	INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
30/03/22	INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
18/01/22	INHIBITOR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
12/11/21	INHIBITOR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
13/08/21	INHIBITOR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
14/05/21	INHIBITOR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
26/03/21	INHIBITOR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
06/01/21	INHIBITOR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
17/12/20	INHIBITOR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
16/11/20	INHIBITOR THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
23/09/20	INHIBITOR THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
25/11/19	HedgePath Pharmaceuticals : INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer	PR